No Detail Found!

Comparison of anlotinib combined with docetaxel versus single docetaxel as second-line treatment beside radiotherapy for advanced non-small cell lung cancer: Efficacy and safety

Author(s)
Huiying Fu Department of Oncology, The 908th Hospital of Chinese People’s Liberation Army Joint Logistic Support Force, Nanchang, Jiangxi Province, China
Chuanqin Ke Department of Oncology, The 908th Hospital of Chinese People’s Liberation Army Joint Logistic Support Force, Nanchang, Jiangxi Province, China
Yongchun Xu Department of Gastroenterology, The 908th Hospital of Chinese People’s Liberation Army Joint Logistic Support Force, Nanchang, Jiangxi Province, China
Haoli Zhang Department of Oncology, The 908th Hospital of Chinese People’s Liberation Army Joint Logistic Support Force, Nanchang, Jiangxi Province, China
Ying Zhong Department of Central Sterile Supply, The 908th Hospital of Chinese People’s Liberation Army Joint Logistic Support Force, Nanchang,Jiangxi Province, China
Yongliang Huang Department of Central Sterile Supply, The 908th Hospital of Chinese People’s Liberation Army Joint Logistic Support Force, Nanchang,Jiangxi Province, China
Abstract
This study compared the efficacy and safety of anlotinib combined with docetaxel versus docetaxel alone in patients with non-small cell lung cancer (NSCLC), assessing overall survival (OS), disease control rate (DCR), and incidence of adverse events (AE). 128 patients with advanced non-small cell lung cancer were randomly divided into ACD group (n=64) and DOC group (n=64). They were treated with ACD and Docetaxel alone, respectively. They received routine blood, urine, stool examination, fecal occult blood, blood biochemistry and tumor markers. The post-treatment CEA and VEGF levels in the ACD group were sharply lower to those in the DOC group (P<0.05). DCR in the ACD group was 79.7%, which was much higher in comparison to the 60.9% in the DOC group (P<0.05). The overall response rate (ORR) of ACD was 23.4%, slightly higher than the 17.2% of DOC. The incidence of hand-foot syndrome (HFS), hypertension, and hemoptysis in the ACD group was significantly higher than in the DOC group. Anlotinib combined with docetaxel for second-line treatment of advanced NSCLC enhanced the DCR, downregulated CEA and VEGF levels and prolonged progression-free survival (PFS) compared to docetaxel alone.
Publication Details
Page(s) 965-973
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 38, Issue: 3, Year: 2025

Request the full text from PASTIC

Keywords
NSCLC, NSCLC, Docetaxel, Anlotinib, second-line treatment
References
Chen Q,Lai Q,Jiang Y,Yao J,Chen Q,Zhang L,Wang C,Zhou Y,Deng M,Xu B M .2022 .Anlotinib exerts potent antileukemic activities in Ph chromosome negative and positive B-cell acute lymphoblastic leukemia via perturbation of PI3K/AKT/mTOR pathway. , 25 : 101516-101516.
Yang Cui G,Y Cui G .2022 .Research progress of anlotinib in the treatment of advanced malignant tumors. Mod. Oncol. Med, 30(16) : 3032-3036.
Fang Y,Pan H,Shou J,Hong W,Guo Q,Yang X,Zhu D,Chen J,Lu L,Rao C,Lan F C .2021 .Anlotinib plus docetaxel versus docetaxel as second-line treatment for advanced non-small cell lung cancer (NSCLC): updated results from a phase I/II study. J. Clin. Oncol., 39(15 suppl)) : e21055-e21055.
Han Q,Hou H,Zhang X .2020 .Research progress on the anti-tumor treatment of domestically produced innovative drug Anlotini. Chin. J. New Drug. Clin. Med, 39(02) : 65-70.
Han Y,Wang J,Sun T,Ouyang Q,Li J,Yuan J,Xu B .2023 .Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer. Signal Transduct. Target. Ther., 8(1) : 429-429.
Hao H .2018 .Anaplastic lymphoma kinase (ALK) receptor tyrosine kinase: Acatalytic receptor with many faces. Int. J. Mol. Sci, 19(11) : 3448-3448.
Isamu O,Hiroshi N,Shogo N,Seiji N,Shunichi S,Hidehito H,Koichi A,Yasuto Y,Haruyasu M,Yukio H,Shinji A,Tomohiro O,Atsushi H,Yuka F,Hiroaki O,Masahiko A,Nobuyuki Y,Yuichiro O,Kazuhiko N .2020 .Comparison of carboplatin plus pemetrexed followed by maintenance pemetrexed with docetaxel monotherapy in elderly patients with advanced nonsquamous non-small cell lung cancer: Aphase 3 randomized clinical trial. JAMA Oncol., 6(5) : e196828.
Ji X,Jing X,Liu Y,Huang J,Yang S,Yun Y .2022 .Clinical application of anlotinib combined with docetaxel: Safe and effective treatment for lung carcinoma. Dis. Markers, 2483816 : 2483816.
Jin Y,Shimizu S,Li Y,Yao Y,Liu X,Si H,Sakurai H,Xiao W H .2023 .Proton therapy (PT) combined with concurrent chemotherapy for locally advanced nonsmall cell lung cancer with negative driver genes. Radiat. Oncol., 18(1) : 189-189.
Li Z,Quan C,Li W,Ji M .2023 .Synergistic effect of docetaxel combined with a novel multi-target inhibitor CUDC-101 on inhibiting human prostate cancer. Pathol. Res. Pract, 252 : 154938-154938.
Lin B,Song X,Yang D,Bai D,Yao Y,Lu N Y .2018 .Corrigendum to “Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1” [Gene 654 (. , 723 : 144119-86.
Liu M,Niu X,Liu H,Chen J .2023 .Germline EGFR mutations in lung cancer (Review). Oncol. Lett., 26(1) : 282-282.
Liu Z,Wang X,Li C,Zhao R .2023 .The function and mechanism of PSMD14 in promoting progression and resistance to anlotinib in osteosarcoma. Cancer Cell Int, 23(1) : 309-309.
Markers D .2023 .Retracted: Clinical application of anlotinib combined with docetaxel: Safe and effective treatment for lung carcinoma. Dis. Markers, 9826032 : 9826032.
Omer HA,Amin K,Grand K .2023 .(Noisy-le-. Cell. Mol. Biol, 69(11) : 81-91.
Parums D .2022 .Editorial: Recent approval of sotorasib as the first targeted therapy for KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC). Med. Sci. Monit, 28 : e938746-e938746.
Pei S,Zhang X,Lu W .2023 .The efficacy of amlotinib hydrochloride combined with docetaxel in the treatment of advanced esophageal cancer and its impact on serum tumor markers and immune function. Chin. J. Clinicians, 51(04) : 443-446.
Taminya A .2023 .Long-term survival of patients with advanced non-small cell lung cancer treated using immune checkpoint inhibitors. Resp, 62(1) : 85-89.
Wang Q,Niu W,Pan H W .2021 .Targeted therapy with anlotinib for a H3K27M mutation diffuse middle glioma patient with PDGFR-α mutation: A case report. Acta Neurochir., 164(8) : 1-4.
Wang Y,Du J,Gong S J .2023 .Analysis of quality of life and prognostic factors in patients with stage I nonsmall cell lung cancer treated with stereotactic radiotherapy. J. Pract. Cancer., 38(07) : 1151-1147.
Wang Z,Wang C,Feng L C .2023 .The efficacy of immunotherapy combined with anlotinib in the treatment of refractory advanced non-small cell lung cancer. Chin. J. Clin. Ration. Drug Use, 16(35) : 74-77.
Wu C .2023 .The combined application of oral administration of anlotinib with docetaxel chemotherapy and intensity modulated radiotherapy in the treatment of early-stage small cell lung cancer after first-line treatment failure. Shandong Med, 63(06) : 51-54.
Yang S,Zhao Y .2023 .Evaluation of the efficacy of amlotinib hydrochloride in the treatment of advanced non-small cell lung cancer. Chin. J. Metall. Ind. Med, 40(04) : 449.
Yang W,Xuan B,Chen M,Li X,He J,Si H,Zhang Y,Front Y .2022 .Comparison of efficacy and safety between immunotherapy and docetaxel monotherapy in NSCLC patients#13. , 12 : 883514-883514.
Zhai X,Liu Y,Liang Z,Wang W,Qin T,Liu SV,Um S,Luo F,Liu J F .2022 .Classical ALK G1202R resistance mutation was identified in a lung adenocarcinoma patient with rare LOC388942-ALK fusion after sequential treatment with ALK-TKIs and anlotinib: A case report. Ann. Transl. Med, 10(21) : 1180-1180.
Yang Zhang L,X Zhang L .2023 .Comment on: quitting smoking at or around diagnosis improves the overall survival of lung cancer patients: Asystematic review and meta-analysis. J. Thorac Oncol., 18(2) : e17-e19.
Zheng W,Sun G,Li Z,Wu F,Sun G,Cao H,Zhou J,Ma Y,Front Y .2022 .The effect of anlotinib combined with anti-PD-1 in the treatment of gastric cancer#13. , 9 : 895982-895982.
Zhou Y,Li F,Zou B,Zhou X,Luo L,Dong S,He Z,Zhang Z,Liao L,Liu H,Cai C,Gu D,Duan X .2023 .β- Arrestin2 promotes docetaxel resistance of castrationresistant prostate cancer via promoting hnRNP A1- mediated PKM2 alternative splicing. Discov. Oncol., 14(1) : 215-215.
Zhu X,Yu Y,Lu S Y .2022 .Frontline treatment of advanced non-small cell lung cancer in the elderly. J. Pract. Oncol., 37(03) : 221-226.
0

Citations

0

Downloads

127

Views